{"entity":{"id":"wolfgang-fendler","kind":"person","name":"Wolfgang P. Fendler","aka":[],"tldr":"A German nuclear medicine doctor at Essen who helped design a scoring system, RECIP, for reading follow-up PSMA scans in prostate cancer patients on lutetium therapy, and who co-writes the field's international imaging guidelines.","summary":"Wolfgang Fendler is vice chair (deputy director, under Ken Herrmann) and head of translational oncology at the University Hospital Essen's Department of Nuclear Medicine, and a member of the German Cancer Consortium (DKTK). He is first or senior author on a series of studies validating Response Evaluation Criteria in PSMA-PET/CT (RECIP 1.0), a framework for reading follow-up PSMA PET scans in men on 177Lu-PSMA radioligand therapy, and co-authored the EANM/SNMMI joint procedure guidelines for both PSMA PET/CT and 177Lu-PSMA radioligand therapy.\n\nHis research also covers real-world outcomes of extended and rechallenge 177Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer, and he received the EAU Prostate Cancer Research Award in 2021 for his work relating PSMA-ligand PET findings to clinical outcomes in non-metastatic castration-resistant prostate cancer.","asOf":"2026-09-22","links":[{"label":"Essen Klinik für Nuklearmedizin, oncology team page","url":"https://nuklearmedizin.uk-essen.de/onkologie/"},{"label":"RECIP 1.0, Radiology / RECIP criteria collaboration site","url":"https://recip-criteria.com/"}],"tags":["PSMA","response criteria","clinician"],"related":["essen-wtz","psma-pet","lu177-radioligand-therapy","ken-herrmann","matthias-eiber","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Vice Chair (deputy director), Department of Nuclear Medicine, University Hospital Essen / University of Duisburg-Essen","institutionId":"essen-wtz","specialisms":["PSMA PET response assessment","radioligand therapy trials","German Cancer Consortium (DKTK) translational research"],"profiles":[{"label":"Essen nuclear medicine department page","url":"https://nuklearmedizin.uk-essen.de/onkologie/"}],"papers":[{"title":"Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","journal":"Journal of Nuclear Medicine","year":2022,"url":"https://recip-criteria.com/"},{"title":"Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2023,"doi":"10.1007/s00259-023-06255-8"},{"title":"PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2023,"doi":"10.1007/s00259-022-06089-w"}]},"route":"/people/wolfgang-fendler/","neighbours":{"institution":[{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/"}],"technology":[{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"}],"person":[{"id":"ken-herrmann","kind":"person","name":"Ken Herrmann","route":"/people/ken-herrmann/"},{"id":"matthias-eiber","kind":"person","name":"Matthias Eiber","route":"/people/matthias-eiber/"}],"isotope":[{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}]}}